SAN FRANCISCO – New preliminary phase II data on a 1-mg dose of NGM-282 and existing data on a 3-mg dose of the nonalcoholic steatohepatitis (NASH) candidate, in development by NGM Biopharmaceuticals Inc., show "unprecedented antifibrotic activity" at week 12 of an open-label study, the study's principal investigator, Stephen Harrison said.